相关实验视频

Updated: Jul 4, 2026

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Published on: May 24, 2018

下一代代糖替代品Rebaudioside D和M在高脂肪饮食小鼠中不会加剧代谢功能障碍

Sangyi Lim^1,2, Min-Jung Park¹, Ki-Nam Yoon³

¹Department of Veterinary Physiology, College of Veterinary Medicine, Chonnam National University, Gwangju 61186, Republic of Korea.

Food chemistry: X

|July 4, 2025

概括

新兴的天然甜味剂rebaudioside D和M没有对小鼠的体重,肝脏或肌肉健康产生不良影响. 这些零热量糖替代品对肠道微生物群产生积极影响,表明它们可能是安全的选择.

科学领域:

代谢健康代谢健康
营养科学营养科学
食品化学食品化学食品化学

背景情况:

对含糖饮料 (SSB) 的日益关注,推动了对零卡路里天然甜味剂的需求.
Stevia 衍生化合物,如 rebaudioside D 和 M,正在作为潜在的糖替代品获得关注.
传统的甜味剂和酸作为评估新型替代品的基准.

研究的目的:

为了调查rebaudioside D和M对健康的影响.
为了比较Rebaudioside D和M与传统的糖替代品和stevioside.
评估对肥胖,肝脏健康,热生成脂肪细胞,骨肌肉和肠道微生物群的影响.

主要方法:

使用小鼠模型研究rebaudioside D和M的影响.
评估的参数包括体重,肝硬化,棕色脂肪组织功能,骨肌肉代谢蛋白质和肠道微生物群组成.
结果与对照组和传统替代品进行了比较.

主要成果:

雷巴奥酸D和M并没有导致体重增加或加重肥胖症.
没有观察到肝脏肥胖症的促进或棕色脂肪组织功能受损.
骨肌肉代谢蛋白质保持不变,肠道微生物群组成受到积极影响,没有不良代谢影响.

结论:

在小鼠模型中,Rebaudioside D和M显示出良好的安全性.
这些零卡路里天然甜味剂不会引起负面的代谢变化.
雷巴化物D和M有潜力成为糖和传统甜味剂的安全替代品,特别有利于肠道健康.

关键词:

我们的肠道微生物群.肥胖问题肥胖问题雷巴乌迪oside D 的使用方法雷巴乌迪奥赛德M M 糖的替代品糖的替代品

更多相关视频

Assessing Whole-Body Lipid-Handling Capacity in Mice

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

Measurement of Fatty Acid β-Oxidation in a Suspension of Freshly Isolated Mouse Hepatocytes

Measurement of Fatty Acid β-Oxidation in a Suspension of Freshly Isolated Mouse Hepatocytes

Published on: September 9, 2021

相关概念视频

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...